Getgoal Duo 1

Lixisenatide activates the GLP-1 receptor and thereby exercises the range of physiological effects generated by GLP-1, which consist of increased insulin secretion, inhibition of glucagon secretion, and decreased gastrointestinal motility alongside the promotion of.

Getgoal duo 1. Again, as in the 4B, body weight and hypoglycemia incidence. Sanofi announced positive results from its Phase 3, GetGoal Duo 1 study of Lyxumia (lixisenatide) in combination with Lantus (insulin glargine;. So far, GetGoal-X, GetGoal-L, GetGoal-L Asia, GetGoal-Mono, GetGoal-S, GetGoal-F1 and GetGoal Duo 1 have reported positive top-line results.

Lixisenatide improved HbA1c, weight with standard GLP-1 safety profile PHILADELPHIA — Once-daily lixisenatide, an investigational GLP-1 agonist, was associated with significant HbA1c. In the GetGoal Duo 1, randomized, double-blind, multicenter study, 8 insulin-naïve patients were treated with insulin glargine (Lantus), which was titrated to reach a target fasting plasma glucose (FPG) of 80-100 mg/dL for a 12-week run-in phase period. For Type 2 diabetes patients treated with basal.

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. The glucagon-like peptide (GLP)-1 receptor agonist lixisenatide (Lyxumia®) was approved for marketing by the European Medicines Agency in February 13 and has been evaluated in a clinical study program called GetGoal. A 24- week, Randomized, Placebo-Controlled Study (GetGoal Duo 1).” Diabetes Care 36.9 (13):.

During the 12-week run-in phase, 8 insulin-naive patients were treated with insulin glargine, which was titrated to reach a target fasting. Results showed that lixisenatide caused mild and transient nausea and vomiting, the most common adverse events, and a limited additional or comparable risk of hypoglycemia. Riddle MC, Forst T, Aronson R et al.

Adjustment of dosage of insulin glargine. A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Lixisenatide as monotherapy (GetGoal-Mono), as add-on to oral antidiabetic drugs (OADs;.

Riddle MC, Forst T, Aronson R, et al. A two-step dosage increase was used with both placebo and lixisenatide (10 μg for 1 week, 15 μg for 1 week, and then -μg maintenance dosage if tolerated), with injections self-administered by participants ≤1 h before breakfast. Once-daily lixisenatide added on to consistently titrated insulin glargine plus oral agents in type 2 diabetes:.

Propensity Score Matched Analysis. The originality of GetGoal DUO 2 is the comparison between add-on of lixisenatide and active treatment (prandial insulin). 21 – 26 The GetGoal-X trial, which compared lixisenatide with twice-daily exenatide, resulted in weight loss of 2.96 kg and 3.98 kg, respectively.

In the GetGoal-Duo-1 trial, both groups gained weight, but patients in the lixisenatide arm gained less than those in the control arm (0.3 kg versus 1.2 kg, respectively;. Sanofi) and OADs. GetGoal Duo 1 and GetGoal-L both achieved the primary efficacy endpoint of HbA1c improvement with an associated significant reduction in PPG.

-1 0 1 GetGoal-L1 GetGoal-L Asia2 GetGoal-Duo 13 e ) ~16.0 (2 mg/dL) 17.8 (3.4 mg/dL) ~13.0 (234 mg/dL) Baseline PPG Lixisenatide Added to Background Insulin:. Riddle MC, Forst T, Aronson R, et al. Change in 2-h PPG and glucose.

It’s free, simple and works on Android phones, iPhones, tablets, computers, and smart displays, like the Google Nest Hub Max. The trials were conducted between July 08 and August 11 across 25 countries (the number of countries and enrolment/completion dates varied by trial). Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:.

A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). The GetGoal program was initiated in May 08. A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

Patients in GetGoal-Duo 1 were from 25 countries and were inadequately controlled (HbA1c 53–86 mmol/mol 7.0–10.0%) on existing OAD therapy. The abstract is titled:. GETGOAL GLP-1 agonist AVE0010 in patients with type 2 diabetes mellitus for glycaemic control and safety evaluation (lixisenatide, µg once daily), GLP-1 RA glucagon-like peptide-1 receptor agonist,.

Prandial Options to Advance Basal Insulin Glargine Therapy:. The GetGoal Duo 1 study evaluated once-daily lixisenatide added on to titrated glargine plus oral agents in type 2 diabetes. Sanofi) for the treatment of patients with type 2.

Further results are expected in 12. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

RIDDLE THOMAS FORST RONNIE ARONSON FRCPC FACE LEOBARDO SAUQUE-REYNA ELISABETH SOUHAMI LOUISE SILVESTRE LIN PING JULIO ROSENSTOCK A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1) OBJECTIVEdWhen oral therapy for type 2 diabetes is ineffective, adding basal insulin improves glycemic control. Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients (GetGoal-O) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. The GetGoal-Duo 1 study ePoster # 807 Session:.

Rosenstock J, Forst T, Aronson R, et al. To date, GetGoal-X, GetGoal-L, GetGoal-L Asia, GetGoal-Mono, GetGoal-S, GetGoal-F1 and GetGoal Duo 1 (also known as EFC*) have reported positive top-line results supporting potential efficacy and safety for lixisenatide. "During a 12-week run-in phase, 8 insulin-naive patients were.

NCT (GetGoal Duo-2 trial). October 12 12:00 - 13:00. GetGoal Duo 1 was a randomized, double-blind, multicenter study assessing the efficacy and safety of lixisenatide compared to placebo in combination with Lantus (insulin glargine;.

GetGoal-M, GetGoal-S) or in combination with basal insulin (GetGoal-L, GetGoal-Duo-1 and GetGoal-L-Asia). Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. If present, SU therapy was discontinued, and patients were initiated on basal insulin therapy with or without MET or a TZD during the run-in phase.

The GetGoal Duo-2 Trial. The GetGoal-Duo 1 study assessed the complementary action of lixisenatide and insulin glargine in patients with type 2 diabetes failing on oral antidiabetes medication. Six randomized, placebo-controlled studies of lixisenatide µg once daily were included in this analysis:.

A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). RESEARCH DESIGN AND METHODS Patients were randomized to lixisenatide once daily or insulin glulisine given once or. Like in 4B, in GetGoal DUO 2 the A1C decreased to similar values with lixisenatide or glulisine 1/d (~7.2%), or glulisine 3/d (~7.0%).

“Adding Once – Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine:. Try Duo for web. Plain language summary available for this article.

A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). The GetGoal Duo-2 Evidence-Based Trial (NCT). OBJECTIVE To provide evidence-based options on how to intensify basal insulin, we explored head-to-head prandial interventions in overweight patients with type 2 diabetes inadequately controlled on basal insulin glargine with or without 1–3 oral antidiabetic agents (OADs).

Advancing Basal Insulin Glargine with Prandial Lixisenatide QD vs Insulin Glulisine QD or TID in T2DM:. The GetGoal program started in May 08 and has enrolled more than 4,500 patients. PS 063 GLP-1 based therapies Berlin 12 Poster Hall 3.

Patients in GetGoal-L Asia were from Japan, Republic of Korea, Taiwan, and the Philippines. Presented at the 72nd Scientific Sessions of the American Diabetes Association, Philadelphia PA, 8-12 June 12 (Abstract 62-OR). Epub 16 May 23.

Patients were randomized to receive lixisenatide or placebo 1:1 in GetGoal-Duo1 and GetGoal-L-Asia, and 2:1 in GetGoal-L. Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes:. In GetGoal Duo 1, lixisenatide in combination with insulin glargine achieved the primary study endpoint of significantly reducing HbA1c with a significant improvement in 2-hour post-prandial.

In GetGoal DUO 2, the head-to-head comparison was between lixisenatide 1/d vs glulisine either 1/d (at the main meal, basal-plus) or 3/d (basal-bolus). Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes:. GetGoal DUO 2 follows the studies GetGoal-L and GetGoal DUO 1 , which have both explored the efficacy and safety of once-a-day add-on of lixisenatide to basal insulin at fixed dose , or to insulin glargine with continuing titration as compared to placebo.

In conclusion, 1) GLP-1-(7-36) amide or -(7-37) inhibits gastric emptying also in normal subjects, 2) physiological doses (0.4 pmol.kg-1.min-1) still have a significant effect, 3) despite the. Secondary Endpoints Change in 2-hr PPG Change in Body Weight. Lantus(R) is the No.1 leading basal insulin product in the world, and the results from GetGoal Duo 1 show that adding lixisenatide to treatment with Lantus(R) can offer significant benefits to patients." "Lixisenatide is a promising new GLP-1 agonist with a mode of action which complements that of basal insulin.

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. These patients were on existing basal insulin therapy with or without a SU. Riddle MC, Forst T, Aronson R, Sauque-Reyna L, Souhami E, Silvestre L, Ping L, Rosenstock J.

The GetGoal Duo-1 trial was the first study to assess the efficacy of lixisenatide in combination with optimally titrated basal insulin in patientswith type2 diabe-tesuncontrolledonOADswhowerenewly initiatinginsulinglargine.Signi ficantreduc-tions in HbA 1c to 7% (53 mmol/mol) and marked PPG reductions were achieved. MC Riddle, T Forst, R Aronson, et al.Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. Therefore, propensity score matching was used to indirectly compare simultaneous administration of iGlarLixi in the LixiLan-O trial (n=469) with sequential therapy, starting with initial insulin glargine 100 U/mL therapy for 12 weeks, followed by addition of lixisenatide in the GetGoal Duo-1 trial in patients with Type 2 diabetes mellitus who.

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. To conduct two exploratory analyses to compare indirectly the efficacy and safety of simultaneous administration of insulin glargine 100 U (iGlar) and the glucagon-like peptide-1 receptor agonist (GLP-1RA) lixisenatide (Lixi) as a single-pen, titratable, fixed-ratio combination (iGlarLixi LixiLan trials) vs sequential administration of iGlar + Lixi (GetGoal Duo trials) in people with. Duo is the highest quality 1 video calling app.

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. GetGoal Duo 1 is a randomized, double-blind, multicenter study, assessing the efficacy and safety of lixisenatide, compared to placebo, in combination with insulin glargine and OADs (mostly metformin). A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients (GetGoal-Duo-2) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. "The results from the GetGoal Duo-2 study reconfirm the therapeutic benefits of Lyxumia(R) as a novel prandial GLP-1 agonist. GETGOAL-L-Asia GETGOAL-Duo-1 Cardiovascular outcome trials for GLP-1 RAs.

A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). A 24-week, randomized, placebo-controlled study.

Riddle, Mattew C.et al. Julio Rosenstock 1 , Bruno Guerci 2 , Markolf Hanefeld 3 , Sandro Gentile 4 , Ronnie Aronson 5 , Francisco J Tinahones 6 , Christine Roy-Duval 7 , Elisabeth Souhami 7 , Marek Wardecki 8 , Jenny Ye 9 , Riccardo Perfetti 9 , Simon Heller 10 , GetGoal Duo-2 Trial Investigators. After a 12-week run-in phase in which insulin glargine was initiated, patients with A1C ≥7% were randomized to μg lixisenatide ( n = 223) or placebo ( n = 223) for 24 weeks while continuing on insulin glargine.